ReviewMolecular pharmaceutics2017
Lipid-Drug Conjugate for Enhancing Drug Delivery.
Review in Molecular pharmaceutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of nanocarriers used in medicine and beyond - definition and categorization framework.Journal of nanobiotechnology · 2025Pooled it
- Stigmasterol-Acylglycerol Conjugates: Chemoenzymatic Synthesis as a Shorter Alternative to Chemical Routes and the Impact of Fatty Acid Chain Length on the Physicochemical Parameters of Liposomes.Molecules (Basel, Switzerland) · 2026Article
- Synthesis and Biological Evaluation of a Lipophilic Vorinostat Prodrug.Chemistry & biodiversity · 2026Article
- Small Molecule Drug Conjugate Hybrids of Naphthalene Sulfonamide and Phospholipid Conjugates Are Microtubule-Disrupting Antitumor Agents.Pharmaceutics · 2026Article
- Lipid Conjugation of a Photoprotective Meadowfoam (Biomolecules · 2026Article
- Fatty Acids in Cancer Therapy: Chemical Conjugates, Nanocarriers, and Therapeutic Opportunities.Molecules (Basel, Switzerland) · 2026Review
- From chain length to cell death: mechanistic basis for ROS-mediated apoptosis induced by saturated fatty acids.Scientific reports · 2026Article
- Molecular Insights into the Incorporation of Platinum-Based Drugs into Lipid Aggregates.ACS omega · 2026Article
- DNA as Drug Carrier: A Hydrophobic β-Cyclodextrin Channel in a Supramolecular Structure.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Artificial lipidation of proteins and peptides: from mechanism to clinical applications.The FEBS journal · 2026Review
- Bioconjugates for improved delivery of oligonucleotide therapeutics to the central nervous system.Advanced drug delivery reviews · 2026Review
- Chitosan-Coated Niosomal Nanocarriers for the Co-Delivery of Glibenclamide and Curcumin in Diabetes Mellitus.Polymers · 2026Article
- Biomimetic liposomes in drug delivery: from design mechanisms to applications.Chemical Society reviews · 2026Review
- Medicinal and Aromatic Plant Oils in Aquafeeds: Mechanistic Perspectives on Growth Promotion, Immunomodulation, and Stress Resilience.Aquaculture nutrition · 2026Review
- Targeted Hepatic Delivery of Bioactive Molecules via Nanovesicles: Recent Developments and Emerging Directions.Journal of personalized medicine · 2025Review
- Design and In Vitro Evaluation of Gambogic Acid-Conjugated Stearic Acid Solid Lipid Nanoparticles for Transferrin Receptor-Mediated Drug Delivery.Pharmaceutical research · 2025Article
- Expanding the Chemical Space of Mechanically Interlocked Peptides (MIPs) via Rational Design and Metabolite Profiling.JACS Au · 2025Article
- Role of Serum Stability and Lipoprotein Interactions in Lipid Structure-Tumor Accumulation Relationship.ACS nano · 2025Article
- Functionalized in Triplicate: A Ring-By-Ring Approach to Tailored Prodiginine Derivatives for Site-Specific Conjugation Through Click Chemistry.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Lipid-drug conjugates (LDCs) are drug molecules that have been covalently modified with lipids. The conjugation of lipids to drug molecules increases lipophilicity and also changes other properties of drugs. The conjugates demonstrate several advantages including improved oral bioavailability, improved targeting to the lymphatic system, enhanced tumor targeting, and reduced toxicity. Based on the chemical nature of drugs and lipids, various conjugation strategies and chemical linkers can be utilized to synthesize LDCs. Linkers and/or conjugation methods determine how drugs are released from LDCs and are critical for the optimal performance of LDCs. In this review, different lipids used for preparing LDCs and various conjugation strategies are summarized. Although LDCs can be administered without a delivery carrier, most of them are loaded into appropriate delivery systems. The lipid moiety in the conjugates can significantly enhance drug loading into hydrophobic components of delivery carriers and thus generate formulations with high drug loading and superior stability. Different delivery carriers such as emulsions, liposomes, micelles, lipid nanoparticles, and polymer nanoparticles are also discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.